CLINICAL TRIALS PROFILE FOR ALCAFTADINE
✉ Email this page to a colleague
All Clinical Trials for ALCAFTADINE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00889330 ↗ | Safety and Efficacy Study of a Eye Drop for Eye Allergy | Completed | Vistakon Pharmaceuticals | Phase 3 | 2009-04-01 | The purpose of this study is to evaluate the efficacy and safety of an anti-allergy eyedrop. |
| NCT01732757 ↗ | A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis | Completed | Allergan | Phase 4 | 2012-11-01 | This study will evaluate the efficacy of Lastacaft® (Alcaftadine 0.25%) and Pataday™ (Olopatadine 0.2%) as compared to each other and to placebo in the prevention of ocular itching associated with allergic conjunctivitis. |
| NCT01808768 ↗ | Ocular Allergy Treatment Practical Impact Trial | Unknown status | Starx Research Center, LLC | Phase 4 | 2013-04-01 | To study the impact of alcaftadine in patients treated with other opthalmic ocular agents (or specific topical opthalmic treatment) in an allergy subspecialist outpatient setting. |
| NCT02555761 ↗ | Safety and Efficacy of Lastacaft® for the Prevention of Itching Associated With Allergic Conjunctivitis in Korea | Completed | Allergan | 2015-10-19 | This post-marketing surveillance study will assess the safety and efficacy of Lastacaft® Opthalmic Solution 0.25% (Alcaftadine) for the prevention of itching associated with Allergic Conjunctivitis as prescribed as standard of care in clinical practice in Korea. | |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ALCAFTADINE
Condition Name
Clinical Trial Locations for ALCAFTADINE
Trials by Country
Clinical Trial Progress for ALCAFTADINE
Clinical Trial Phase
Clinical Trial Sponsors for ALCAFTADINE
Sponsor Name
